Rituximab monotherapy versus glucocorticoid therapy for adult minimal change disease: a retrospective study on noninferiority
Adequate RTX monotherapy is noninferior to adequate glucocorticoids in inducing and maintaining remission in adult MCD patients without AKI, with fewer adverse effects and better adherence, and may be considered as a first-line treatment option for adult MCD patients without AKI.
Authors
- Caifeng Gao
- Guangyu Yao (ORCID: https://orcid.org/0000-0002-3406-7612)
- Bing Chen (ORCID: https://orcid.org/0000-0003-1038-0847)
- Haiping Wang (ORCID: https://orcid.org/0000-0002-3056-1656)
- Rong Wang (ORCID: https://orcid.org/0000-0003-1341-4731)
- Xiaoyun Li (ORCID: https://orcid.org/0000-0002-6901-027X)
- Yujiao Sun
- Na Li (ORCID: https://orcid.org/0000-0001-9080-1300)
Institutions
- Zhangqiu City People's Hospital (CN)
- Shandong Provincial Hospital (CN)
- Hanzhong People's Hospital (CN)
- Jinan City People's Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Nephrology
- Published
- 2025-12-09
- DOI
- https://doi.org/10.3389/fneph.2025.1715546
- Primary Topic
- Adrenal Hormones and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Natural Science Foundation of Shandong Province
- Shandong First Medical University